https://scholars.lib.ntu.edu.tw/handle/123456789/484093
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | CHIH-HUNG HSU | en_US |
dc.contributor.author | Kang Y.K. | en_US |
dc.contributor.author | Yang T.-S. | en_US |
dc.contributor.author | CHIA-TUNG SHUN | en_US |
dc.contributor.author | YU-YUN SHAO | en_US |
dc.contributor.author | Su W.-C. | en_US |
dc.contributor.author | Sandoval-Tan J. | en_US |
dc.contributor.author | Chiou T.-J. | en_US |
dc.contributor.author | Jin K. | en_US |
dc.contributor.author | CHIUN HSU | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.creator | Cheng A.-L.;Hsu C.;Jin K.;Chiou T.-J.;Sandoval-Tan J.;Su W.-C.;YU-YUN SHAO;Shun C.-T.;Yang T.-S.;Kang Y.K.;Hsu C.-H. | - |
dc.date.accessioned | 2020-04-10T12:16:09Z | - |
dc.date.available | 2020-04-10T12:16:09Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879774804&doi=10.1159%2f000350841&partnerID=40&md5=7a2f5a313d6351a3d1064aeec41ae248 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/484093 | - |
dc.description.abstract | Objectives: The bevacizumab/erlotinib combination was reported with high clinical activity for advanced hepatocellular carcinoma (HCC) by a phase II study conducted in the USA. This multicenter study across several Asian countries was to evaluate the safety and efficacy of the combination in this population. Methods: Patients with histology-proven HCC, advanced disease and Child-Pugh class A liver function received bevacizumab 5 mg/kg intravenously every 2 weeks and erlotinib 150 mg/day orally as first-line therapy. The primary end point was progression-free survival at 16 weeks (PFS-16W). The expression of epidermal growth factor receptor (EGFR), phospho-AKT and vascular endothelial growth factor, the microvessel density and the EGFR gene copy number in HCC tissues were correlated with treatment efficacy. Results: Fifty-one patients were enrolled. The PFS-16W was 35.3% (95% CI 22.4-49.9), the median PFS was 2.9 months (95% CI, 1.3-4.4) and the median overall survival was 10.7 months (95% CI, 6.2-15.2). Grade 3/4 toxicities were uncommon, including rash, acne (10% each), diarrhea (6%) and gastrointestinal bleeding (4%). None of the evaluated biomarkers correlated with disease control or PFS. Conclusions: Bevacizumab plus erlotinib showed good tolerability and modest activity in this Asian cohort. Further studies are warranted to identify the predictive biomarkers of this combination. Copyright ? 2013 S. Karger AG, Basel. | - |
dc.relation.ispartof | Oncology (Switzerland) | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | bevacizumab; epidermal growth factor receptor; erlotinib; hepatitis B surface antigen; sorafenib; vasculotropin; bevacizumab; epidermal growth factor receptor; erlotinib; protein kinase B; vasculotropin; acne; adult; advanced cancer; alopecia; anemia; article; Asian; capillary density; Child Pugh score; correlation analysis; diarrhea; drug efficacy; drug eruption; drug safety; epistaxis; fatigue; female; gastrointestinal hemorrhage; gene dosage; hand foot syndrome; histopathology; human; hyperbilirubinemia; hypertension; immunohistochemistry; liver cell carcinoma; liver function; lung hemorrhage; major clinical study; male; melena; metastasis; multicenter study; nausea; neutropenia; outcome assessment; overall survival; paronychia; phase 2 clinical trial; priority journal; progression free survival; protein expression; proteinuria; stomach ulcer; stomatitis; treatment response; advanced hepatocellular carcinoma; advanced hepatocellular carcinoma; aged; Article; cancer tissue; disease control; human tissue; leukoencephalopathy; open study; rash; therapy; United States; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian Continental Ancestry Group; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, Epidermal Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor A | - |
dc.title | Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1159/000350841 | - |
dc.identifier.pmid | 23838576 | - |
dc.identifier.scopus | 2-s2.0-84879774804 | - |
dc.relation.pages | 44-52 | - |
dc.relation.journalvolume | 85 | - |
dc.relation.journalissue | 1 | - |
item.fulltext | no fulltext | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Cancer Administration and Coordination Center | - |
crisitem.author.dept | Forensic Medicine | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0003-0495-973X | - |
crisitem.author.orcid | 0000-0002-0468-4468 | - |
crisitem.author.orcid | 0000-0001-7334-1912 | - |
crisitem.author.orcid | 0000-0002-1122-0055 | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。